The Next Generation of Clinically Validated Antibody Drug Conjugates: Expanding Indications & Improving Outcomes

8:30 am - Tuesday 9th March 2027

Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen the therapeutic index and bring patient benefit
Showcasing late-breaking clinical data from novel tumour targets in underserved populations
Highlighting future priorities for next-generation ADC development with differentiated safety profiles and future standard of care therapies